1. Home
  2. CRSP vs LRN Comparison

CRSP vs LRN Comparison

Compare CRSP & LRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • LRN
  • Stock Information
  • Founded
  • CRSP 2013
  • LRN 2000
  • Country
  • CRSP Switzerland
  • LRN United States
  • Employees
  • CRSP N/A
  • LRN N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • LRN Other Consumer Services
  • Sector
  • CRSP Health Care
  • LRN Real Estate
  • Exchange
  • CRSP Nasdaq
  • LRN Nasdaq
  • Market Cap
  • CRSP 4.0B
  • LRN 3.5B
  • IPO Year
  • CRSP 2016
  • LRN 2007
  • Fundamental
  • Price
  • CRSP $47.25
  • LRN $100.54
  • Analyst Decision
  • CRSP Buy
  • LRN Buy
  • Analyst Count
  • CRSP 19
  • LRN 5
  • Target Price
  • CRSP $73.69
  • LRN $89.40
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • LRN 1.6M
  • Earning Date
  • CRSP 11-05-2024
  • LRN 10-22-2024
  • Dividend Yield
  • CRSP N/A
  • LRN N/A
  • EPS Growth
  • CRSP N/A
  • LRN 53.12
  • EPS
  • CRSP N/A
  • LRN 5.50
  • Revenue
  • CRSP $202,829,000.00
  • LRN $2,110,972,000.00
  • Revenue This Year
  • CRSP N/A
  • LRN $13.18
  • Revenue Next Year
  • CRSP $526.27
  • LRN $8.32
  • P/E Ratio
  • CRSP N/A
  • LRN $18.23
  • Revenue Growth
  • CRSP 19.31
  • LRN 11.55
  • 52 Week Low
  • CRSP $43.42
  • LRN $54.81
  • 52 Week High
  • CRSP $91.10
  • LRN $103.98
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.94
  • LRN 67.80
  • Support Level
  • CRSP $50.60
  • LRN $99.15
  • Resistance Level
  • CRSP $59.07
  • LRN $103.98
  • Average True Range (ATR)
  • CRSP 2.84
  • LRN 2.55
  • MACD
  • CRSP -0.35
  • LRN 0.40
  • Stochastic Oscillator
  • CRSP 7.48
  • LRN 70.48

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

About LRN Stride Inc.

Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional, and Private Pay Schools and Other.

Share on Social Networks: